These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26121651)

  • 1. Polymorphonuclear Cell Functional Impairment in Relapsing Remitting Multiple Sclerosis Patients: Preliminary Data.
    Allizond V; Scutera S; Rossi S; Musso T; Crocillà C; Cavalla P; Trebini C; Marra ES; Cuffini AM; Banche G
    PLoS One; 2015; 10(6):e0131557. PubMed ID: 26121651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behçet's disease heterogeneity: cytokine production and oxidative burst of phagocytes are altered in patients with severe manifestations.
    Perazzio SF; Soeiro-Pereira PV; de Souza AW; Condino-Neto A; Andrade LE
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S85-95. PubMed ID: 26394190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
    Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
    J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal radiosensitivity in patients with multiple sclerosis.
    Milenkova M; Milanov I; Kmetska K; Deleva S; Popova L; Hadjidekova V; Groudeva V; Hadjidekova S; Domínguez I
    Mutat Res; 2013 Sep; 749(1-2):3-8. PubMed ID: 23994714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRYAB modulates the activation of CD4+ T cells from relapsing-remitting multiple sclerosis patients.
    Quach QL; Metz LM; Thomas JC; Rothbard JB; Steinman L; Ousman SS
    Mult Scler; 2013 Dec; 19(14):1867-77. PubMed ID: 23736536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
    Lindquist S; Hassinger S; Lindquist JA; Sailer M
    Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated production of leukemia inhibitory factor in immune cells of relapsing remitting multiple sclerosis patients.
    Levy YA; Mausner-Fainberg K; Vaknin-Dembinsky A; Amidror T; Regev K; Karni A
    J Neuroimmunol; 2015 Jan; 278():85-9. PubMed ID: 25595256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
    Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of caspofungin in restoring the impaired phagocyte-dependent innate immunity towards Candida albicans in chronic haemodialysis patients.
    Scalas D; Banche G; Merlino C; Giacchino F; Allizond V; Garneri G; Patti R; Roana J; Mandras N; Tullio V; Cuffini AM
    Int J Antimicrob Agents; 2012 Jan; 39(1):73-6. PubMed ID: 22055531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.
    Khademi M; Bornsen L; Rafatnia F; Andersson M; Brundin L; Piehl F; Sellebjerg F; Olsson T
    Eur J Neurol; 2009 Apr; 16(4):528-36. PubMed ID: 19220425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis.
    Veroni C; Marnetto F; Granieri L; Bertolotto A; Ballerini C; Repice AM; Schirru L; Coghe G; Cocco E; Anastasiadou E; Puopolo M; Aloisi F
    J Neuroinflammation; 2015 Jul; 12():132. PubMed ID: 26169064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.
    Boppana S; Mindur JE; Balashov KE; Dhib-Jalbut S; Ito K
    J Neuroimmunol; 2013 Dec; 265(1-2):68-74. PubMed ID: 24200257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low and dysregulated production of follistatin in immune cells of relapsing-remitting multiple sclerosis patients.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Karni A
    J Neuroimmunol; 2011 Sep; 238(1-2):96-103. PubMed ID: 21880375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of season on cytokine expression in multiple sclerosis and healthy subjects.
    Stewart N; Taylor B; Ponsonby AL; Pittas F; van der Mei I; Woods G; Walters H
    J Neuroimmunol; 2007 Aug; 188(1-2):181-6. PubMed ID: 17628701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetylcysteine effect on the luminol-dependent chemiluminescence pattern of reactive oxygen species generation by human polymorphonuclear leukocytes.
    Stolarek R; Białasiewicz P; Nowak D
    Pulm Pharmacol Ther; 2002; 15(4):385-92. PubMed ID: 12220944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
    Gurevich M; Gritzman T; Orbach R; Tuller T; Feldman A; Achiron A
    J Neuroimmunol; 2010 Apr; 221(1-2):87-94. PubMed ID: 20347159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis.
    Rolland A; Jouvin-Marche E; Saresella M; Ferrante P; Cavaretta R; Créange A; Marche P; Perron H
    J Neuroimmunol; 2005 Mar; 160(1-2):195-203. PubMed ID: 15710473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.